BIOMARK’S LIQUID BIOPSY ASSAY LEVERING METABOLOMICS DEMONSTRATES STRONG PERFORMANCE FOR EARLY LUNG CANCER DETECTION
Vancouver, British Columbia – ( March 24th, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “A High-Performing Plasma Metabolite Panel for Early-Stage Lung Cancer Detection” has been published in the peer-reviewed journal Cancers, validating BioMark’s technology to detect early-stage (I/II) non-small cell lung cancer […]
BIOMARK’S LIQUID BIOPSY SCIENTIFIC PAPER TO BE FEATURED AS COVER ON CANCERS UPCOMING ISSUE
![biomakrs liquid biopsy scientific paper to be featured on cover on cancers upcoming issue](https://www.biomarkdiagnostics.com/wp-content/uploads/2021/05/biomakrs-liquid-biopsy-scientific-paper-to-be-featured-on-cover-on-cancers-upcoming-issue.jpg)
Vancouver, British Columbia – (August 19th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “Liquid Biopsy in Lung Cancer Screening: The Contribution of Metabolomics. Results of A Pilot Study” will be on cover of Cancers. Rashid Ahmed, President and CEO, says, “This latest paper […]
A Good Choice for MMJ and Biotech Market Opportunity
![Good Choice for MMJ and Biotech Market Opportunity](https://www.biomarkdiagnostics.com/wp-content/uploads/2016/03/Good-Choice-for-MMJ-and-Biotech-Market-Opportunity.jpg)
A Good Choice for MMJ and Biotech Market Opportunity Gaalen Engen, Stockhouse.com Original article: http://www.stockhouse.com/news/newswire/2016/03/03/a-good-choice-for-mmj-and-biotech-market-opportunity For almost fifty years, his was a trusted voice when it came to sports and news. Bill Good, following in the footsteps of his father, “Breathless Bill”, established himself as a national broadcasting icon over a long career which included […]